Inactive Instrument
Company Vical Incorporated Nasdaq
Stocks
US9256022032
Biotechnology & Medical Research
Business description: Vical Incorporated
Sales by Activity: Vical Incorporated
| Fiscal Period: December | 2019 (USD) | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) |
|---|---|---|---|---|---|
Pharmaceuticals | 7.92M | 1.82M | 404K | 6.94M | 8.01M |
Geographical breakdown of sales: Vical Incorporated
| Fiscal Period: December | 2019 (USD) | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) |
|---|---|---|---|---|---|
United States | 7.92M | 1.82M | 404K | 6.94M | 8.01M |
Executive Committee: Vical Incorporated
| Manager | Title | Age | Since |
|---|---|---|---|
Albert Marchio
CEO | Chief Executive Officer | 74 | - |
Nancy Seretta
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/2016 |
Aaron Fox-Collis
DFI | Director of Finance/CFO | - | 01/06/2022 |
Aron Aizenstat
PRN | Corporate Officer/Principal | - | - |
Sue Fattor
HRO | Human Resources Officer | - | - |
Company details: Vical Incorporated
Bio Therapeutic Drugs
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.41% | -6.33% | +43.43% | +71.02% | 63.29B | |
| -0.15% | +3.11% | +10.29% | +72.56% | 54.89B | |
| +0.57% | +4.64% | +12.82% | +89.79% | 53.28B | |
| +0.37% | +3.07% | +28.23% | +51.53% | 45.81B | |
| -1.21% | +0.95% | +20.44% | +128.58% | 43.46B | |
| -0.37% | -1.20% | +252.94% | +568.54% | 40.23B | |
| +0.05% | +6.75% | +14.48% | +56.75% | 33.45B | |
| +1.19% | -5.84% | +27.86% | -0.65% | 23.7B | |
| -0.38% | +4.55% | +37.71% | +28.10% | 23.76B | |
| Average | +0.28% | +0.33% | +49.80% | +118.47% | 42.43B | |
| Weighted average by Cap. | +0.38% | +0.55% | +48.17% | +122.11% |
